[UPDATE] Ordinary Index Rebalancing in the Solactive Genomics Index | May 2022

In the ordinary rebalance the following composition will be implemented effective open 16.05.2022:

2SEVENTY BIO INC-W/I
AGILENT TECHNOLOGIES INC
ALLOGENE THERAPEUTICS INC
ALNYLAM PHARMACEUTICALS INC
ARROWHEAD PHARMACEUTICALS INC
BEAM THERAPEUTICS INC
BIOMARIN PHARMACEUTICAL INC
BIONANO GENOMICS INC
BIONTECH SE
BLUEBIRD BIO INC
CAREDX INC
CARIBOU BIOSCIENCES INC
CRISPR THERAPEUTICS AG
CELLECTIS SA
EDITAS MEDICINE INC
FULGENT GENETICS INC
GENSCRIPT BIOTECH CORP
GILEAD SCIENCES INC
GRAPHITE BIO INC
ILLUMINA INC
INTELLIA THERAPEUTICS INC
INVITAE CORP
MODERNA INC
MYRIAD GENETICS INC
NANOSTRING TECHNOLOGIES INC
NATERA INC
PACIFIC BIOSCIENCES OF CALIFORNIA INC
QIAGEN NV
REGENXBIO INC
ROCKET PHARMACEUTICALS INC
SANGAMO THERAPEUTICS INC
SAREPTA THERAPEUTICS INC
SORRENTO THERAPEUTICS INC
STOKE THERAPEUTICS INC
TAKARA BIO INC
ULTRAGENYX PHARMACEUTICAL INC
UNIQURE B.V.
VERACYTE INC
VERTEX PHARMACEUTICALS INC
VERVE THERAPEUTICS INC